Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Ram I. Mahato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3588-0434; OpenAlex author ID A5051052380; NIH RePORTER profile ID 6615593. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 21)
Trials
0
Grants
3
Labs led
2
Collaborators
22
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers, 1 grant · 2018: 1 paper, 1 grant · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 2 papers, 1 grant

Papers 23

  1. Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer. Last author DOI 10.1016/j.actbio.2025.12.049↗
  2. Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218618↗
  3. Drug delivery and targeting to chemoresistant pancreatic cancer. First author DOI 10.1016/j.canlet.2024.216648↗
  4. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer. Last author DOI 10.1016/j.jconrel.2023.12.053↗
  5. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model. Last author DOI 10.1038/s41420-024-01920-9↗
  6. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. First author DOI 10.1016/j.canlet.2023.216462↗
  7. Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Last author DOI 10.1016/j.jconrel.2020.09.052↗
  8. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Last author DOI 10.1126/sciadv.abd6764↗
  9. ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer. Last author DOI 10.1021/acsami.9b02756↗
  10. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. Last author DOI 10.1007/s11095-017-2303-3↗
  11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Last author DOI 10.1016/j.canlet.2017.05.007↗
  12. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.7b00355↗
  13. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Last author DOI 10.1038/s41598-017-01942-7↗
  14. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Last author DOI 10.1021/acs.biomac.5b01419↗
  15. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.5b00971↗
  16. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. Last author DOI 10.1016/j.addr.2014.09.006↗
  17. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Last author DOI 10.1021/mp500847s↗
  18. Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Last author DOI 10.1111/bcp.12620↗
  19. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2014.04.053↗
  20. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Last author DOI 10.1016/j.canlet.2012.10.008↗
  21. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma. Last author DOI 10.1021/bc400032x↗
  22. Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer. Last author DOI 10.1021/mp3002792↗
  23. Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Last author DOI 10.1517/17425247.2012.722079↗

Grants 3

  1. Nanomedicine of Hedgehog and AKT/ERK Dual Inhibitors for Pancreatic Cancer R01CA266759↗
  2. Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer R01GM113166↗
  3. Polymeric Nanomedicines of Small Molecules and miRNA for Treating Pancreatic Canc R01EB017853↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Virender Kumar · 10 shared papers, 2013–2024 · strength 1.72
  2. Yashwardhan Ghanwatkar · 3 shared papers, 2024–2026 · strength 1.17
  3. Goutam Mondal · 7 shared papers, 2015–2018 · strength 0.59
  4. Surinder K. Batra · 1 shared paper, 1 shared grant, 2015–2018 · strength 0.40
  5. Nilkamal Pramanik · 1 shared paper, 2024 · strength 0.31
  6. Deepak Chitkara · 5 shared papers, 2012–2015 · strength 0.27
  7. Amit Chaudhary · 3 shared papers, 2017 · strength 0.26
  8. Rajan Sharma Bhattarai · 2 shared papers, 2020–2021 · strength 0.25
  9. Xiaofei Xin · 2 shared papers, 2019–2020 · strength 0.24
  10. Saud Almawash · 2 shared papers, 2017–2018 · strength 0.24
  11. Vinod Kumar · 2 shared papers, 2017–2020 · strength 0.19
  12. Anupama Mittal · 3 shared papers, 2013–2015 · strength 0.19
  13. Krishna Kattel · 2 shared papers, 2015–2017 · strength 0.15
  14. Wěi Li · 1 shared paper, 2021 · strength 0.13
  15. Tatiana K. Bronich · 1 shared paper, 2021 · strength 0.13
  16. Stephen W. Behrman · 3 shared papers, 2012–2013 · strength 0.13
  17. Melek Karaca · 1 shared paper, 2016 · strength 0.08
  18. Michael K. Danquah · 2 shared papers, 2012 · strength 0.08
  19. Pankaj Kumar Singh · 1 shared paper, 2016 · strength 0.08
  20. Surendra Kumar Shukla · 1 shared paper, 2016 · strength 0.08
  21. Jean L. Grem · 1 shared paper, 2015 · strength 0.06
  22. Saurabh Pratap Singh · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.